ABBV has rebounded after Humira patent cliff, with Skyrizi and Rinvoq driving growth. Rising estimates and a pipeline set to ...

Detailed price information for Interactive Brokers (IBKR-Q) from The Globe and Mail including charting and trades.

While early, the results indicate drugs known as ITK inhibitors have the potential to match or surpass the efficacy observed ...

Nearly half of US rheumatologists expect Gazyva to meaningfully reshape SLE treatment pathways, while CAR T-cell therapy is ...

Let's consider three of them: Eli Lilly ( LLY +0.52%), AbbVie ( ABBV 0.31%), and Intuitive Surgical ( ISRG 1.15%). Here's why ...

Now, it’s worth noting Stock Advisor’s total average return is 955 % — a market-crushing outperformance compared to 196% for ...

The article " AbbVie Call Options Spike 2,599%: Tracking the Big Bet " first appeared on MarketBeat.

Both Skyrizi and its cousin Rinvoq have landed in the annual top three, in varying positions, since 2022. That was once again the case in 2025, when Skyrizi retained its place at the top and Rinvoq ...

AbbVie’s lost exclusivity for Humira is offset by immunology and neurology sales, diversified by its emerging oncology ...

AbbVie leads a Zacks Analyst Blog roundup highlighting strong pharma execution, AI-driven chip gains and an aviation rebound.

Primarily known as an immunology and neuroscience company, AbbVie wanted to put the biopharma world on notice during its J.P.